FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma By Ogkologos - July 18, 2025 756 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer June 27, 2025 GreaterGood Is Donating Thousands of Masks to Help Animal Shelters Stay... September 17, 2020 37-Year-Old Mom Breaks American Marathon Record January 21, 2022 FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Chronic Myeloid... November 26, 2024 Load more HOT NEWS Strengthening EU Support for Rare Cancers under the 2028–2034 Multiannual Financial... Taking Control – Risks vs. Benefits Breast Cancer Patient Fights To Have Mastectomy During COVID-19 Restrictions And... Study Identifies Potential Warning Signs of Colorectal Cancer in Younger Adults
